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Abstract
Heparanase is an enzyme involved in extracellular matrix remodelling and heparan sulphate proteoglycan catabolism. It is
secreted by metastatic tumour cells, allowing them to penetrate the endothelial cell layer and basement membrane to
invade target organs. The release of growth factors at the site of cleaved heparan sulphate chains further enhance the
potential of the tumour by encouraging the process of angiogenesis. This leads to increased survival and further
proliferation of the tumour. Aptamers are single or double stranded oligonucleotides that recognise specific small
molecules, peptides, proteins, or even cells or tissues and have shown great potential over the years as diagnostic and
therapeutic agents in anticancer treatment. For the first time, single stranded DNA aptamers were successfully generated
against the active heterodimer form of heparanase using a modified SELEX protocol, and eluted based on increasing affinity
for the target. Sandwich ELISA assays showed recognition of heparanase by the aptamers at a site distinct from that of a
polyclonal HPSE1 antibody. The binding affinities of aptamer to immobilised enzyme were high (7610
7 to 8610
7 M
21)a s
measured by fluorescence spectroscopy. Immunohistochemistry and immunofluorescence studies demonstrated that the
aptamers were able to recognise heparanase with staining comparable or in some cases superior to that of the HPSE1
antibody control. Finally, matrigel assay demonstrated that aptamers were able to inhibit heparanase. This study provides
clear proof of principle concept that nucleic acid aptamers can be generated against heparanase. These reagents may serve
as useful tools to explore the functional role of the enzyme and in the future development of diagnostic assays or
therapeutic reagents.
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Introduction
Heparanase is a b-1,4-endoglycosidase enzyme [1] that
participates in extracellular matrix (ECM) degradation and
remodelling [1]. The nascent polypeptide is a 543 amino acid
pre-proenzyme which, after removal of the signal peptide
sequence in the endoplasmic reticulum, undergoes proteolytic
processing in late endosomes/lysosomes by cathepsin-L like
proteases [2] at sites Glu
109-Ser
110 and Gln
157-Lys
158, yielding
an N-terminal 8kDa polypeptide, a C-terminal 50kDa polypeptide
and between them; a 6kDa linker polypeptide [3]. The 50 and
8kDa polypeptides associate to form a heterodimeric active
enzyme, whilst the 6 kDa linker is excised and degraded [3].
Heparanase activity is associated with activated leukocytes, mast
cells, placental tissue and macrophages and the enzyme is secreted
by activated CD4
+ T cells [4,5,6], platelets [3], neutrophils and
metastatic cells [7].
Upon secretion of heparanase from metastatic tumour cells, the
enzyme hydrolyses the glycosidic bonds of heparan sulphate chains
attached to proteoglycans to products 10–20 sugar units in length
[8], leading to penetration of the endothelial cells of blood vessels
and target organs by the tumour cell. Liberation of bound
cytokines and growth factors sequestered by heparan sulphate
chains in tissues [9] further facilitates growth of the tumour and
promotes angiogenesis and proliferation of secondary tumours
[10]. Levels of heparanase expression in tumour cells correlate
with their metastatic potential; elevated levels of heparanase
mRNA and protein have been found in cancer patients who show
significantly shorter postoperative survival times than patients
whose heparanase levels are normal [10,11]. In addition to its
function in cancer progression, heparanase enzyme also plays a
major role in the activity of inflammatory cells. The enzyme has
been detected in a variety of immune cells including T and B cells,
macrophages, neutrophils and mast cells. It has been shown to
mediate extravasation through the endothelial barrier via the
remodeling of ECM heparan sulphate, which then allows
trafficking to the sites of inflammation [7,12,13]. Heparanase
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different cancers, for example, acute myeloid leukaemia [14],
bladder, brain [15], breast [16], colon [17], gastric [18],
oesophageal [19], oral [20], and pancreatic [11], suggesting that
it may be a suitable target for drug therapy. Currently available
inhibitors of heparanase include neutralising antibodies [21],
peptides [22] and small molecules [23,24] as well as heparin [25]
and sulphated oligosaccharide mimics of heparan sulphate
[26,27].
Aptamers are short DNA or RNA oligonucleotides developed
for diagnostic and therapeutic use that display high binding affinity
and specificity for target molecules [28,29,30]. The affinity of
aptamers has been compared with that of antibodies (i.e. in the
nanomolar range), but as aptamers are mostly smaller (8–25kDa
compared to 150kDa), they can both penetrate tissues and be
cleared from the plasma within minutes of intravenous adminis-
tration, without triggering an immune response, which can be
useful when using them as diagnostic agents [31]. For therapeutic
use they are able to retain their function and binding character-
istics upon modification with other moieties to improve their
stability and solubility, whilst reducing their toxicity and plasma
clearance [31,32,33,34,35,36,37]. Typically, aptamers are from 22
to 100 bases in length, and contain a region of variable sequence,
flanked by known sequences, which are used for amplification and
identification purposes. A large repertoire of different sequence
combinations (typically in the region of 10
15) in the central domain
creates many different folding arrangements, specificities for
different molecules and binding affinities. Aptamers are typically
produced based on the SELEX (systematic evolution of ligands by
exponential enrichment) procedure [38], although a number of
other selection methodologies are currently available [39,40,41].
In this study, aptamers displaying high affinity and specificity
were generated against the active enzyme heparanase using a
modified SELEX procedure. Their binding to heparanase was
characterised using ELISAs, quartz crystal microbalance (QCM)
and fluorescence quenching experiments and aptamers were found
to interact with the enzyme with equilibrium association constants
in the range of 10
7 M
21 and could detect heparanase at 10 nM in
buffer. Aptamers bound to the enzyme at a site different to that
recognised by the antibody used as a control, but in cell and tissue
labelling studies they demonstrated comparable and in one
instance superior recognition and staining, as well as the ability
to inhibit heparanase action in matrigel assays. Thus, aptamers
have shown the ability to specifically recognise purified heparanase
as well as heparanase expressed in cells and tissue, offering the
potential for further therapeutic and diagnostic development.
Results
Selection Generated Potentially High Affinity Aptamer
Species
Aptamers were selected against heparanase using a modified
single-round SELEX protocol. Briefly, the aptamer library was
incubated with heparanase in a Top Yield PCR tube for one hour
at room temperature and eluted using a salt step gradient. Eluates
were desalted using Microcon filters and amplified by PCR.
Aptamers were detected by agarose gel electrophoresis (figure 1) in
all salt fractions. The 1.5 M NaCl and 3.0 M NaSCN elutions
were selected for cloning as they were expected to contain
aptamers with the highest affinity for the target. After sequencing,
81% of clones from the 3.0 M NaSCN elution had identical
sequences, whilst a lower consensus was exhibited in clones from
1.5 M NaCl elution, with 2 identical species and areas of similarity
in many others (table 1).
The homologous aptamer sequences from both 1.5 M NaCl
and 3.0 M NaSCN elutions were analysed using the Mfold [42,43]
program (figure 2) which predicts three-dimensional structures by
calculating their minimum Gibbs free energies as well as the free
energy of folding of each base pair at 37uC. Both the variable and
primer regions were analysed, as the primer regions often help to
confer stability upon the aptamer and are therefore frequently
implicated in their structure. Based on the structure adopted by
the identical species in the 1.5 M NaCl elution, a truncated 30
nucleotide sequence, predicted to form a stem loop; ‘1.5 M short’,
and the 73 nucleotide full length sequence; ‘1.5 M long’ were
synthesised for further testing. The sequence generated from
3.0 M NaSCN was synthesised as 55 nucleotides ‘3.0 M’, due to
this number of nucleotides being consistently implicated in the
predicted structures.
Aptamer Species Bind with High Affinity to the Target,
Heparanase
Competition ELISAs determined that a heparanase polyclonal
antibody and the selected aptamers do not compete for the same
binding site (data not shown) as there was no reduction in signal
from the polyclonal antibody upon aptamer addition. Therefore,
their binding was investigated by a sandwich ELISA, where both
antibody and aptamer were utilised (figure 3). 59-biotinylated
aptamers were immobilised via streptavidin to the plate surface.
After incubation with increasing concentrations of heparanase,
then successive incubations with polyclonal antibody, horseradish
peroxidase conjugated secondary antibody and addition of
chromogen and stop solution, an increase in signal corresponding
with the increase in heparanase concentration was observed. An
unrelated aptamer generated a low background signal only,
confirming specific binding of the selected aptamers to hepar-
anase. The graph of 1.5 M long and 3.0 M aptamers shows a
plateau at 100 nM heparanase, with a plateau at 70 nM for 1.5 M
short aptamer, when binding sites become exhausted. Also, the
absorbance reaches a higher maximum for the two longer
aptamers which would suggest that more heparanase is retained
by them. This may be explained by their size, in that more 9kDa
1.5 M short aptamers may be obscured and be subject to steric
hindrance by one 58kDa heparanase molecule than the 22kDa
1.5 M long or 17kDa 3.0 M aptamer.
Aptamers were subsequently used to capture and bind
heparanase from solution (100–800 nM) in QCM experiments.
Figure 4 shows the sensograms obtained for aptamer 1.5 M short
and confirms a decrease in frequency upon addition of
heparanase, which only reverses marginally after the PBS wash;
generating a resonance frequency decrease of 37.46Hz, thus
suggesting binding of heparanase. Upon addition of heparanase,
the resonance frequency declined in a dose-dependent manner.
Baseline characteristics were restored by exposure to EDTA and
3.0 M NaSCN, consistent with desorption.
Fluorescence quenching titrations were carried out using the
natural intrinsic fluorescence of heparanase (due to the solvato-
chromic emission peak of tryptophan) to determine the binding
interactions of the three aptamers, analysed by a quadratic
equation [44]. Figure 5 shows quenching of the maximal
fluorescence of heparanase with 1.5 M short, long and 3.0 M
aptamers by 38%, 23% and 31% respectively. Equilibrium
association constants for 1.5 M short, 1.5 M long and 3.0 M
aptamers were calculated to be 7.3, 8.3 and 7.6610
7 M
21
respectively, suggesting that although the primer regions included
in the 1.5 M long sequence do appear to have an effect on the
interaction with heparanase, this is not a significant one. The
quenching percentage from the heparanase-selected aptamers
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more of the six tryptophan residues. As all tryptophans are spread
within the 50kDa subunit at sites 199, 220, 295, 340, 365 and 405,
it is likely that the binding of the aptamer would be closer to one or
two tryptophans at a time, clearly accounting for the percentage of
change observed in the fluorescence emission. It is even possible
that the aptamer binds to the 8kDa subunit (which contains no
tryptophan residues) or N-terminus, which carries a positive
charge at physiological pH so would attract the negatively charged
aptamer, but the aptamer binding to this part of the heterodimer
causes such changes in the structure that they would affect the
overall fluorescence emission of the tryptophans in the 50kDa
subunit.
Aptamer Species Bind Heparanase with High Affinity and
Specificity in Cell and Tissue Studies
To test for recognition and specificity of the aptamers in
comparison with the heparanase polyclonal antibody, paraffin-
embedded placental tissue was sectioned and subjected to
immunohistochemistry (figure 6), and immunofluorescent labelling
was performed on different invasive cell lines (figure 7).
In first trimester placenta stained with polyclonal anti-hepar-
anase antibody, staining was seen in the nuclei and cytoplasm of
the cytotrophoblast-syncytiotrophoblast bilayer lining the intervil-
lous space of the chorionic villi, and in endothelial cells of the
developing blood vessels. No staining was observed when a mouse
antibody was used as a negative control. Of the aptamers, 1.5 M
short stained the cytoplasm of the outer syncytiotrophoblasts and
1.5 M long exhibited a staining pattern almost identical, although
Figure 1. A 2% agarose gel to determine the presence of aptamers in each salt elution from 0.5 M NaCl to 3.0 M NaSCN. Bands at
75bp were observed in all fractions except the negative control, suggesting that different species of aptamer had bound with different affinities,
removed in each salt concentration.
doi:10.1371/journal.pone.0037938.g001
Table 1. Sequence consensus of aptamers eluted from 1.5 M NaCl and 3.0 M NaSCN.
1.5 M NaCl selection 3.0 M NaSCN selection
--------AAGAAGACTAGCGATGAAGAGCGCT-- 25
CGGATTATTCGAACTCTTCCAATGA------------ 25
----TACTAACTACTCGTACGCAAACGGA------- 25
-----AATAGCAAGTTGTAAGTTGAAGAAA----- 25
---ACTTAATTTGCACTTACCATATGGC--------- 25
--TAATTGCTTCACCCTTACAAACCAG---------- 25
-TCTCTTTCTTGACGCTCTATAAGCG----------- 25
GCGATCGGGATAATCTGCTATAAGA---------- 25
-------TATTCATACG—GAACAGAATTCTCCC- 25
---------CCAATATAA-GAATATTATTGTCTCA- 25
-----CATTGGAAAAATCCGAAAGTGATTA----- 25
-----CAGATTAACATACCAAATCTAATTA----- 25
---------ATGGACTTTTGAATGTGGCAACAAA- 25
---------ATGGACTTTTGAATGTGGCAACAAA- 25
---------GTCGCCTTTTCACTTCACTAGGGTA- 25
GGACAGTCAGTCACCATGATTATTT---------- 25
-------CACTCAACAGCCTTATTTCCCAATG--- 25
-----GAAAGCAAACGTCCTAATTCCAGAA--- 25
-------AACTAAATCTCCAAACAACTTACTG— 25
-CACCAGGTTCCATGTCCTAAACTTA--------- 25
-------TAATACCTCGCCAGCTACGTCACAG--- 25
TTTAACGTATTTATTCAAGCTCGTA--- 25
TTTAACGTATTTATTCAAGCTCGTA--- 25
TTTAACGTATTTATTCAAGCTCGTA--- 25
TTTAACGTATTTATTCAAGCTCGTA--- 25
TTTAACGTATTTATTCAAGCTCGTA--- 25
TTTAACGTATTTATTCAAGCTCGTA--- 25
TTTAACGTATTTATTCAAGCTCGTA--- 25
TTTAACGTATTTATTCAAGCTCGTA--- 25
TTTAACGTATTTATTCAAGCTCGTA--- 25
TTTAACGTATTTATTCAAGCTCGTA--- 25
TTTAACGTATTTATTCAAGCTCGTA--- 25
TTTAACGTATTTATTCAAGCTCGTA--- 25
TTTAACGTATTTATTCAAGCTCGTA--- 25
TTTAACGTATTTATTCAAGCTCGTA--- 25
TTTAACGTATTTATTCAAGCTCGTA--- 25
TTTAACGTATTTATTCAAGCTCGTA--- 25
TTTAACGTATTTATTCAAGCTCGTA--- 25
TTTAACGTATTTATTCAAGCTCGTA--- 25
TTTAACGTATTTATTCAAGCTCGTA--- 25
TTTAACGTATTTATTCAAGCTCGTA--- 25
TTTAACGTATTTATTCAAGCTCGTA--- 25
TTTAACATATTTATTCAAGCTCGTA--- 25
---TATATATTCCTACACATCTAACTTA 25
doi:10.1371/journal.pone.0037938.t001
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more uniformly throughout the stroma and not in the same
pattern as the antibody, which suggests non-specific staining.
In term placenta, heparanase antibody staining remains
localised to syncytiotrophoblasts, and blood vessels. The negative
control is unstained. 1.5 M long aptamer shows an identical
staining pattern and intensity to the heparanase antibody. 1.5 M
short stains fetal capillaries and 3.0 M shows a low level of stromal
staining, which suggests once again non-specific binding.
PL4, a first trimester immortalised trophoblast cell line, when
fluorescently labelled with the anti-heparanase antibody (figure 7),
showed high levels of heparanase throughout the cytoplasm and in
the nucleus of the cells, with some notable variation in intensity
between adjacent cells. 1.5 M short and 1.5 M long aptamers
showed similar or higher heparanase levels and staining patterns to
that of the antibody. 3.0 M was also able to recognise heparanase
in PL4 cells, but to a lesser extent than its counterparts. Stromal
cells isolated from placental villous mesenchyme, contain a low
level of heparanase both in tissue sections and in culture, as
detected by specific antibody; aptamer binding patterns were
entirely consistent with this level of expression. Interestingly,
1.5 M short aptamer has stained the cytoplasm of the cells to a
higher degree than both the 1.5 M long and 3.0 M aptamers and
the heparanase antibody.
Aptamer Species Inhibit Heparanase in a Matrigel Cell
Invation Assay
The Matrigel invasion assay was performed to investigate
whether binding of aptamers to heparanase inhibited the enzyme’s
function of hydrolysing heparan sulphate proteoglycans (figure 8).
This experiment was conducted using ovarian carcinoma cell line,
OC MZ-6; a cell line previously shown to contain heparanase in
immunofluorescence experiments [21]. A polyclonal anti-hepar-
anase antibody that had also previously been used in this assay
demonstrating inhibitory effects [21] was used as a positive
control, and showed once more that significantly decreased
numbers of cells had invaded the Matrigel, with 40.667.13 cells
compared to no inhibitor at 74.4634.28 (p=0.0164) and
compared with a negative control antibody at 66.6615.77
(p=0.0008). Anti-heparanase aptamers 1.5 M short, 1.5 M long
and 3.0 M were all used as potential inhibitors (at a concentration
of 1 mM) and of these, 1.5 M long significantly outperformed the
heparanase antibody in its inhibitory function with 26.965.49 cells
compared with no inhibitor (p=0.0032) and with the negative
control antibody (p,0.0001). 1.5 M short aptamer also demon-
strated inhibition of invasion, though not at a significant level, and
aptamer 3.0 M demonstrated little or no inhibiton of heparanase
activity. These results suggest that the 1.5 M long aptamer is a
significant inhibitor of cell invasion in this model.
Discussion
Aptamers were successfully selected against the active hetero-
dimer form of heparanase using an optimised, modified SELEX
protocol based on interruption of the interactions formed between
protein and aptamer by high salt content. Aptamers generated
from 1.5 M NaCl and 3.0 M NaSCN elutions each suggested one
prominent species based on sequence homology. Based on their
predicted structures using Mfold structure predicting software, the
aptamers were truncated to remove any nucleotides not implicated
in structure formation for downstream considerations, such as cost
and improved tissue penetration, before carrying out preliminary
binding experiments. The binding data obtained from ELISA,
QCM and fluorescence quenching titrations confirmed that the
aptamers bind heparanase with high affinity, possibly close to two
of its six tryptophan residues, but at a different site to that of the
antibody, which is still able to bind heparanase simultaneously
with the aptamers. Equilibrium dissociation constants for the
aptamers generated to heparanase were calculated as 13.7 nM,
12 nM and 13 nM for 1.5 M short, long and 3.0 M respectively,
Figure 2. Mfold predicted structures for products of 1.5 M NaCl (above) and 3.0 M NaSCN (below) selection.
doi:10.1371/journal.pone.0037938.g002
Figure 3. Streptavidin ‘sandwich’ ELISA testing binding of 187 nM ‘1.5 M short’, ‘1.5 M long’, ‘3.0 M’ and an unrelated aptamer to
heparanase, with a no aptamer negative control. Schematic diagram (right) of the ELISA.
doi:10.1371/journal.pone.0037938.g003
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groups for their targets [35,45,46,47,48]. Immunohistochemistry
and immunofluorescence data suggest that aptamers 1.5 M short,
long and 3.0 M are able to recognise and bind heparanase in vitro
in the presence of other cell components and proteins. 1.5 M long
and short aptamers showed the most consistent staining patterns
respectively, compared with that of the antibody; in some cases
exceeding the antibody in intensity and suggesting better
recognition. As aptamers 1.5 M long and short originated from
the same sequence and therefore share some structural features or
binding nucleotides, these results were not totally unexpected.
These results were consistent with those from the Matrigel
invasion assay, where aptamer 1.5 M long outperformed the
anti-heparanase antibody in inhibiting invasion of OC MZ-6 cells,
suggesting a potential use as a heparanase inhibitor. Future
experiments in other cell invasion or metastasis models will be
necessary to determine the best inhibitor for in vivo studies and
potentially the ideal aptamer length for inhibitory activity; a
truncated aptamer may be favoured in cell and tissue-based studies
as, due to its size, it may show increased tissue penetration.
Although aptamer 3.0 M was eluted from the 3.0 M NaSCN wash
and displayed high binding affinity in ELISA, QCM and
fluorescence quenching, it did not perform as well in cell and
tissue labelling studies or in the Matrigel invasion assay. Studies
are now underway to further investigate the effect of the aptamer
binding on both HS digestion and the non enzymatic roles of the
protein. Other areas of future research are to map the specific
binding regions of the aptamers on heparanase using truncated
proteins, which may help to explain the lack of inhibitory action of
the 3.0 M aptamer. Heparin-like molecules can exert anti-
inflammatory effects and reduce leukocyte adhesion and traffick-
ing, partly through their inhibition on heparanase activity [49,50].
Future experiments will probe inflammatory model systems with
specific heparanase DNA aptamers to address whether they can
also influence the processes of immune cell diapedesis and
extravasation. This paper demonstrates that aptamers can be
Figure 4. Binding sensogram (a) showing decrease in frequency of crystal immobilised with 1.5 M short aptamer exposed to
different concentrations of heparanase. Higher concentrations of heparanase exhibited a greater decrease in frequency. Binding and
regeneration sensogram (b) for addition of 800 nM heparanase to a quartz crystal immobilised with 1.5 M short aptamer. After a PBS wash, a Dfr of
37.46 Hz was observed, confirming heparanase was retained and bound. Washing with EDTA and 3.0 M NaSCN allowed almost total regeneration of
the crystal.
doi:10.1371/journal.pone.0037938.g004
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be useful tools to examine the functional role of the protein and in
diagnostic assay development or therapeutic application as
heparanase inhibitors.
Materials and Methods
Selection Including Cloning and Sequencing
Aptamer library (59–GGGAGACAAGAATAAACGCTCAA-
25N-TTCGACAGGAGGCTCACAACAGGC-39) (University of
Nottingham, UK) was firstly amplified exponentially with 10 mM
forward (59–GGGAGACAAGAATAAACGCTCAA-39) and re-
verse primer (59-GCCTGTTGTGAGCCTCCTGTCGAA-39
both from University of Nottingham, UK) to yield multiple
species of double stranded DNA, which were then amplified using
350 mM forward primer only in a single stranded PCR, yielding
multiple species of single stranded DNA aptamers. 150 nM
human recombinant active heparanase protein (kindly supplied
by Dr Edward McKenzie, University of Manchester, UK [51])
diluted in 100 mM salt solution, pH 6.5 (100 mM NaCl, 20 mM
KCl, 5 mM MgCl2 all purchased from Sigma Aldrich Ltd,
Gillingham, UK) was adsorbed to a Top Yield PCR tube (NUNC
supplied by Fisher Scientific, Loughborough, UK) by overnight
incubation at 4uC, after which any unbound heparanase was
removed with a wash step using 100 mM salt solution. 100 ml
amplified single-stranded library was incubated inside the hepar-
anase-adsorbed tube, then the tube was sealed and gently agitated
for one hour at room temperature. This step was repeated for a
further 300 ml of amplified library so that the maximum aptamer
species were in proximity to the heparanase molecules. Unbound
and low-affinity bound species were removed by incubating 50 ml
0.2 M elution solution, pH 6.5 (0.2 M NaCl, 2.66 mM KCl, and
0.6 mM MgCl2) within the tube on a shaker for 5 minutes. The
eluate was removed and retained. Elution of bound aptamers was
achieved by using a salt gradient ranging from 300 mM to 1.5 M
in 100 mM increments, with a final elution of 3.0 M NaSCN
(Sigma Aldrich Ltd, Gillingham, UK), whilst retaining the eluates
separately. The eluates were desalted using Microcons filters
(Millipore, supplied by Fisher Scientific, Loughborough, UK) with
a 3kDa molecular weight cut off, then amplified in a PCR to yield
double-stranded DNA using 0.25 mM of each forward and reverse
primer (a negative control, using water instead of DNA was also
amplified at this stage). 10 ml from each eluate, plus the negative
control and a 25bp DNA ladder were run on a 2% agarose gel to
check for the presence of DNA aptamers. Fractions with the
highest affinity species (from the highest concentrated salt elutions)
were cloned into Top 10 chemically competent cells using
pCRH2.1-TOPOH Vector from the TOPOH TA CloningH Kit
(Invitrogen, Paisley, UK). Aptamer-positive colonies were then
sequenced by Macrogen Inc, Korea and the resulting sequences
Figure 5. Fluorescence quenching titrations of 250 nM heparanase by 1.5 M short (a), 1.5 M long (b), and 3.0 M NaSCN (c)
aptamers.
doi:10.1371/journal.pone.0037938.g005
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software [53,54].
ELISAs
187 nM 59 biotinylated aptamers (Eurofins; Ebersberg, Ger-
many) were immobilised to the wells of a Maxisorp ELISA plate
(NUNC supplied by Fisher Scientific, Loughborough, UK) via
2.5 mg/ml NeutrAvidinH (Invitrogen, Paisley, UK) in PBS (10 mM
phosphate buffer, 2.7 mM potassium chloride and 137 mM
sodium chloride, pH 7.4, Sigma Aldrich Ltd, Gillingham, UK)
overnight at 4uC. After the plate was washed three times with wash
buffer (5% Tween 20 in PBS), sample wells were blocked with
10 mg/ml BSA (Sigma Aldrich Ltd, Gillingham, UK) in PBS for
20 minutes at room temperature. After three washes in wash
buffer, heparanase was added to sample wells in series between 0
and 200 nM in assay diluent (0.1% Tween 20, 72 mM BSA in
PBS), and incubated for one hour at room temperature. After a
further three washes in wash buffer, polyclonal rabbit anti-
heparanase IgG (kindly supplied by Professor Paul Brenchley,
University of Manchester, UK) [21] was added at a concentration
of 200 nM to all sample wells and incubated for one hour at room
temperature. After three washes in wash buffer, 1/700 dilution of
peroxidase-conjugated goat anti-rabbit secondary antibody (Sigma
Aldrich Ltd, Gillingham, UK) was incubated in all sample wells for
one hour at room temperature, after which, the wells were washed
in wash buffer once again. Chromogen containing tetramethyl-
benzidine (TMB, Sigma Aldrich Ltd, Gillingham, UK) as substrate
(100 mM Sodium acetate, 3 mM citric acid, 0.1% TMB in
DMSO, 0.04% H2O2) was incubated in each well for 30 minutes,
followed by addition of 10% H2SO4 to halt the reaction. The plate
Figure 6. Immunohistochemistry (IHC) of paraffin embedded first trimester and term placenta tissue sections using heparanase
polyclonal antibody, ‘1.5 M short’, ‘1.5 M long’ and ‘3.0 M’ aptamers, anti-cytokeratin-7 antibody plus a negative control mouse
antibody.
doi:10.1371/journal.pone.0037938.g006
Figure 7. Fluorescence (green) of PL4 and stromal cells stained with heparanase polyclonal antibody, ‘1.5 M short’, ‘1.5 M long’ and
‘3.0 M’ aptamers plus a negative control. Nuclei were stained blue.
doi:10.1371/journal.pone.0037938.g007
Development of Aptamers against Heparanase (HPSE1)
PLoS ONE | www.plosone.org 9 June 2012 | Volume 7 | Issue 6 | e37938was read at 450 nm using a Bio-Tek EL808 Ultra Microplate
Reader with Datamax software.
Quartz Crystal Microbalance
Experiments were carried out according to Liss et al [55], using
a research quartz crystal microbalance (QCM) from Maxtek Inc.
Gold surfaces of each 5MHz crystal (Testbourne Ltd, Basingstoke,
UK) were cleaned with ice-cold piranha solution (1 volume 30%
H2O2 added to 4 volumes concentrated H2SO4). Crystals were
immersed in ice-cold H2O, and then transferred to an oven to dry
at 100uC for at least an hour. Activation of gold surfaces was
achieved by adding 4 mg/ml 3,39 dithiodipropionic acid (DSP) in
water-free N,N-dimethylacetamide (DMA) (both from Sigma
Aldrich Ltd, Gillingham, UK), sealing the crystal within a
chamber and incubating for 15 minutes at room temperature.
The crystals were washed three times with sterile PBS. 1 mg/ml
streptavidin diluted in sterile PBS was deposited onto the crystal
surface and crystals were sealed in a chamber and incubated
overnight at 4uC. The crystals were washed five times with PBS,
and then blocked by adding 0.025% BSA in PBS and incubating
for one hour at room temperature. 59 biotinylated aptamers,
diluted to 2 mM in PBS were added after being heated to 95uC
and cooled on ice, and incubated for one hour at room
temperature. The crystals were washed well in PBS and used
immediately.
To measure the binding of heparanase to the aptamers
immobilised on the gold surface, the crystal was placed in the
flow cell which was connected to a pump. Samples were drawn
through into the flow cell in a stop-flow manner. PBS was run
through the system for one minute on fast flow, then the pump was
halted, the program and monitoring switched on, the capacitance
adjusted, and the crystal left to equilibrate in the PBS contained
within the flow cell for one hour or until the reading was stabilised.
After pausing the program and taking care not to introduce any air
into the system, human recombinant polymorphic heparanase
diluted in PBS was added to the flow cell, using the pump to pull
the liquid through very slowly, then the pump was halted and the
program was resumed. When the readings had stabilised, the
program was paused and the crystal was washed using the pump to
pull 10 ml PBS through the system, the pump was ceased and the
readings resumed. After the readings had settled, the program was
paused and the crystal was regenerated with 10 ml 100 mM
EDTA, then 3.0 M NaSCN (both from Sigma Aldrich Ltd,
Gillingham, UK) before the experiment ended. The crystal was
kept at 4uC in a chamber of PBS containing 0.02% sodium azide
until the next experiment. The results, displayed as Dfr (change in
resonance frequency), are inversely related to the mass at the
surface of the crystal (Dm) as explained in the Sauerbrey equation
[55]. Hence, when mass is deposited at the crystal’s surface, the
resonance frequency decreases.
Fluorescence Quenching Experiments
Experiments were performed using a Horiba Jobin Yvon
Fluoromax-P fluorimeter, with the sample in a 100 ml fluorescence
cuvette. Emission spectra were acquired between 300 and 420 nm
with an excitation wavelength of 280 nm and integration time of
1s, at 5 nm increments and at room temperature. After
performing the acquisition on 250 nM heparanase in salt solution,
aptamer was titrated to the following final concentrations in the
cuvette, mixed and an acquisition taken immediately: 25 nM,
50 nM, 100 nM, 200 nM, 400 nM. Results were analysed using
Microcal Origin 6 and the equilibrium association constant (KA)
determined using the equation described by Missailidis and Brady
[56].
Cell Culture and Tissue Collection
Immunohistochemistry, immunofluorescence and Matrigel in-
vasion studies were carried out within the Maternal and Fetal
Health Research Centre at The University of Manchester. All
media and supplements were purchased from Invitrogen Ltd
(Paisley, UK).
First trimester placental samples from women undergoing
elective terminations of pregnancy between 8–12 weeks gestation
and term placental samples were obtained from St. Mary’s
Hospital, Manchester. Written informed consent was obtained
from all patients and ethical approval was obtained from Central
Manchester Local Research Ethics Committee (03/CM/031).
Cell lines were cultured to 80% confluency for the following
experiments and media were supplemented with 10% FBS, L-
glutamine (2 mM), penicillin (100 IU/ml) and streptomycin
Figure 8. OC MZ-6 cells cultured in medium supplemented with anti-heparanase antibody, 1.5 M short, 1.5 M long and 3.0 M
aptamers. The negative controls were represented as no inhibitor and a control mouse antibody. Figures are representative of the average of
triplicate experiments and error bars show standard deviation of the mean.
doi:10.1371/journal.pone.0037938.g008
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in 50% DMEM 50% Ham’s F12 supplemented with 1% non-
essential amino acids and first trimester transformed PL4
trophoblasts were cultured in Ham’s F10 medium. Ovarian
carcinoma cell line OC MZ-6 was cultured in DMEM containing
10 mM HEPES, 116 mg/L arginine and 36 mg/L asparagine.
Immunoperoxidase Staining of Tissue
Wax embedded samples of first trimester and term placenta
were sectioned at 5 mm. Slides were warmed for 10 min at 60uCt o
soften the wax, then deparaffinised in xylene and alcohol, and
rinsed in tap water. Slides were immersed in citrate buffer (2.94g
sodium citrate in 1l of dH2O, pH 6.0, with 500 ml Tween 20) and
microwaved at high temperature for a total of 10 min. After
cooling, endogenous peroxide activity was blocked by placing
slides in methanol containing 0.4% (v/v) HCl and 0.5% (v/v)
H2O2 for 30 min. After rinsing in running water, the slides were
washed for 5 min in TBS. Sections were blocked for 30 min with
5% BSA in TBS, and then primary antibody/59 biotinylated
aptamers were added in TBS (1:100 dilutions for anti-heparanase
and anti-cytokeratin 7, neat for control mouse antibody and
500 nM for all aptamers) and left overnight at 4uC in humidity
chamber. After washing slides for 365 min in TBS, secondary
antibodies were incubated at 1:200 dilutions for 1h at room
temperature to relevant sections and aptamer-labelled sections
were incubated with TBS only. Slides were washed three times for
5 min each in TBS, and then avidin peroxidase was added to all
sections at 5 mg/ml in TBS and incubated at room temperature
for 1h, then washed off with TBS. 3,39-Diaminobenzidine
tetrahydrochloride (DAB) was used to develop the avidin
peroxidase (280 ml TBS +20 ml DAB. 45 mlH 2O2 was added
before use). Slides were washed in tap water and counterstained
with Meyers’ haematoxylin for 5 min, then once more washed
with tap water. Slides were dipped in acid alcohol solution to
remove excess stain for five seconds and then immersed in tap
water for 5 min. Slides were dehydrated and mounted with large
coverslips using xylene alternative mountant.
Immunofluorescence
PL4 and placental stromal cells were fixed in 4% paraformal-
dehyde for 15 min, permeabilised by incubating them in 0.1%
Triton X100 in PBS for 10 min, then washed in PBS. Primary
antibody/biotinylated aptamers in PBS were added and incubated
for 1h at room temperature (1:100 dilutions for anti-heparanase
and anti-cytokeratin 7, neat for control mouse antibody and 1:200
dilutions for all aptamers). After 365 min washes in PBS,
secondary antibodies were added at 1:200 to Hpa1 and control
mouse labelled coverslips only and incubated for 1h at room
temperature (aptamer-labelled coverslips were left in PBS). After
washing in PBS (365 min), streptavidin-FITC conjugate was
added to all coverslips at a 1:50 dilution of stock and incubated for
1h at room temperature underneath a cover to preserve
fluorescence. After a further 3 PBS washes, coverslips were blotted
on a soft tissue and mounted using Vectashield mounting medium
(Vector), containing propidium iodide.
Matrigel Invasion Assay Method
10 mm tissue culture inserts with an 8 mm pore size (Nunc,
Fisher Scientific, UK) were placed into each experimental well of a
sterile 24-well plate (Nunc, Fisher Scientific, UK). One coverslip
per experiment was sterilised in IMS to be used as an indicator of
cell confluency throughout the experiment. 20 ml Matrigel (BD
Discovery Labware, Bedford, MA, USA) previously diluted to
working concentration; (1:8 in serum-free medium) was spread
over each insert then left to dry in the incubator for 30 min.
500 ml medium was added around the edge of each insert and
then 400 ml medium plus 6610
4 cells in 100 ml medium was
placed on the top of the Matrigel and left to adhere for 1h in the
incubator. The medium from both the insert and the well was
removed then replaced with aptamer/antibody/control solution
(all at 1:100 dilutions in fresh medium); 500 ml each into the insert
and the well, and the plate was incubated for 24h. The cells were
fixed in 4% paraformaldehyde for 15 min and permeabilised in
0.1% Triton X100 for 10 min, then stored in PBS @4uC until
they were ready to be stained. The insides of each membrane were
wiped with a cotton bud to remove all cells, leaving only the cells
on the underside, which were then stained with freshly filtered
haematoxylin. After a PBS wash, the inserts were plunged into a
beaker of hot water to activate the stain. The insides of each
membrane were once again wiped with a cotton bud and removed
from the transwell, then placed on slides and mounted. The slides
were viewed under light microscope at610 magnification, eight to
ten representative areas were selected and the cells counted. Data
were represented as the mean 6 standard deviation and an
unpaired two-tailed t-test was conducted to assess the significance
of the results.
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